As drugmakers race to develop the next big weight loss pill, Eli Lilly may have an edge
Publishing timestamp: 2023-06-28 13:35:14
Summary
Drugmakers are competing to develop effective, convenient, and potentially affordable obesity pills. Eli Lilly's orforglipron seems to be leading the race with strong efficacy data and once-daily convenience. However, pivotal data from other pharmaceutical companies is still pending, and pricing remains uncertain. Novo Nordisk's oral semaglutide and Pfizer's danuglipron are also in the running, but face challenges such as dietary restrictions and dosing frequency. Ultimately, the competition in the weight loss pill space is heating up, with the potential for new data to change the current landscape.
Sentiment: MIXED
Keywords: biotech and pharmaceuticals, lilly drn, business, pharmaceuticals, biotechnology, fda, health care industry, business news, pfizer inc, novo nordisk a/s, weight management,
Source: https://www.cnbc.com/2023/06/28/eli-lilly-pfizer-novo-nordisk-weight-loss-pills.html